Literature DB >> 23660543

The effects of silent cerebral ischemic lesions on the prognosis of idiopathic Parkinson's disease.

In-Uk Song1, Young-Do Kim, Hyun-Ji Cho, Sung-Woo Chung.   

Abstract

INTRODUCTION: Recent studies have shown that the presence of cerebrovascular lesions may play an important role in determining the presence and severity of neurodegenerative disease. However, the relationship between cerebrovascular disease and idiopathic Parkinson's disease (IPD) has received little attention. Several reports on the impact of cerebrovascular disease on the clinical status of patients with IPD remain controversial. We conducted a 2-year follow-up study to evaluate whether or not silent cerebral ischemic lesions (SIL) contribute to the progression of IPD.
METHODS: Thirty IPD patients without SIL (only-IPD) and twenty-six IPD patients with SIL (IPDS) were enrolled in this study. All patients underwent brain magnetic resonance imaging (MRI) twice, once at baseline and again at 2-years, to evaluate brain lesions including SIL. The progression of motor severity between the two groups was compared and analyzed.
RESULTS: Two years after the first visit, there was no significant difference in the daily dose of dopamine agonist and levodopa between only-IPD and IPDS patients. Changes in motor severity during the 2-year period were not significantly different between the only-IPD and IPDS group.
CONCLUSIONS: The results of our study suggest that minor cerebral ischemic changes in patients with IPD do not have significant effects on the progression of motor severity in IPD. However, to verify and strengthen these findings, brain MRI and clinicopathological studies involving a large cohort of IPD patients to explore further the relative contribution of vascular and neurodegenerative factors to the prognosis of IPD.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23660543     DOI: 10.1016/j.parkreldis.2013.04.006

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  6 in total

Review 1.  The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature.

Authors:  Branislav Veselý; Angelo Antonini; Ivan Rektor
Journal:  J Neural Transm (Vienna)       Date:  2015-10-19       Impact factor: 3.575

2.  A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants.

Authors:  Katie J Ryan; Charles C White; Kruti Patel; Jishu Xu; Marta Olah; Joseph M Replogle; Michael Frangieh; Maria Cimpean; Phoebe Winn; Allison McHenry; Belinda J Kaskow; Gail Chan; Nicole Cuerdon; David A Bennett; Justin D Boyd; Jaime Imitola; Wassim Elyaman; Philip L De Jager; Elizabeth M Bradshaw
Journal:  Sci Transl Med       Date:  2017-12-20       Impact factor: 17.956

3.  Development of Parkinson Disease and Its Relationship with Incidentally Discovered White Matter Disease and Covert Brain Infarction in a Real-World Cohort.

Authors:  David M Kent; Lester Y Leung; Eric J Puttock; Andy Y Wang; Patrick H Luetmer; David F Kallmes; Jason Nelson; Sunyang Fu; Chengyi Zheng; Ellen M Vickery; Hongfang Liu; Alastair J Noyce; Wansu Chen
Journal:  Ann Neurol       Date:  2022-08-17       Impact factor: 11.274

4.  Association of homocysteine, folate, and white matter hyperintensities in Parkinson's patients with different motor phenotypes.

Authors:  Yuan Shen; Zhi-Feng Dong; Ping-Lei Pan; Gang Xu; Jun-Ying Huang; Chun-Feng Liu
Journal:  Neurol Sci       Date:  2019-05-04       Impact factor: 3.307

5.  Parkinson's disease might increase the risk of cerebral ischemic lesions.

Authors:  In-Uk Song; Ji-Eun Lee; Do-Young Kwon; Jeong-Ho Park; Hyeo-Il Ma
Journal:  Int J Med Sci       Date:  2017-03-11       Impact factor: 3.738

6.  Exploring the association between Cerebral small-vessel diseases and motor symptoms in Parkinson's disease.

Authors:  Ying Wan; Wenjian Hu; Jing Gan; Lu Song; Na Wu; Yuzhen Chen; Zhenguo Liu
Journal:  Brain Behav       Date:  2019-02-27       Impact factor: 2.708

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.